The urokinase-type plasminogen activator system in cancer metastasis: A review

International Journal of Cancer

Volumn 72, Issue 1, 1997, Pages 1-22

  Andreasen, Peter A ^a   Kjøller, Lars ^a   Christensen, Lise ^b   Duffy, Michael J ^c  

^a AARHUS UNIVERSITY   (Denmark)

^b Rigshospitalet   (Denmark)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; APOLIPOPROTEIN; BASIC FIBROBLAST GROWTH FACTOR; BLOOD CLOTTING FACTOR 12A; FIBRIN; FIBRONECTIN; GLYCOSYLPHOSPHATIDYLINOSITOL; GROWTH FACTOR; INTEGRIN; KALLIKREIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROPHAGE ACTIVATING FACTOR; METALLOPROTEINASE; NEUROTOXIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEASE NEXIN I; PROTEINASE; RECEPTOR; SCATTER FACTOR; SCLEROPROTEIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; UROKINASE; VITRONECTIN;

CELL INVASION; CELL MIGRATION; ENDOCYTOSIS; ENZYME ACTIVITY; GENE; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL MOVEMENT; HUMANS; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; RECEPTORS, CELL SURFACE; SERINE ENDOPEPTIDASES; SERPINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030788411     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z     Document Type: Review

References (340)

1. ACHBAROU, A., KAISER, S., TREMBLAY, G., STE-MARIE, L.G., BRODT, P., GOLTZMAN, D. and RABBANI, S.A., Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res., 54, 2372-2377 (1994).
2. ANDREASEN, P.A., GEORO, B., LUND, L.R., RICCIO, A. and STACEY, S.N., Plasminogen activator inhibitors: hormonally regulated serpins. Mol. cell. Endocrinol., 68, 1-19 (1990).
3. ANDREASEN, P.A., PETERSEN, L.C. and DANØ, K., Diversity in catalytic properties of single-chain and two-chain tissue-type plasminogen activator. Fibrinolysis, 5, 207-215 (1991).
4. ANDREASEN, P.A., SOTTRUP-JENSEN, L., KJØLLER, L., NYKJAER, A., MOESTRUP, S.K., MUNCH PETERSEN, C. and GLIEMANN, J., Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett., 338, 239-245 (1994).
5. ANICHINI, E., FIBBI, G., PUCCI, M., CALDINI, R., CHEVANNE, M. and DEL ROSSO, M., Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse tibroblasts transfected with human urokinase receptor. Exp. Cell Res., 213, 438-448 (1994).
6. APPELLA, E., ROBINSON, E.A., ULLRICH, S.J., STOPPELLI, M.P., CORTI, A., CASSANI, G. and BLASI, F., The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J. biol. Chem., 262, 4437-4440 (1987).
7. ARGRAVES, K.M., BATTEY, F.D., MACCALMAN, C.D., MCCRAE, K.R., GÅFVELS, M., KOZARSKY, K.F., CHAPPELL, D.A., STRAUSS, J.F. and STRICKLAND, D.K., The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J. biol. Chem., 270, 26550-26557 (1995).
8. BASTHOLM, L., ELLING, F., BRÜNNER, N. and NIELSEN, M.H., Immunoelectron microscopy of the receptor for urokinase plasminogen activator and cathepsin D in the human breast cancer cell line MDA-MB-231. Acta pathol. microhiol. immunol. Scand., 102, 279-286 (1994a).
9. BASTHOLM, L., NIELSEN, M.H., DE MEY, J., DANØ, K., BRÜNNER, N., HØYER-HANSEN, G., RØNNE, E. and ELLING, F., Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane. Biotechnol. Histochem., 69, 61-67 (1994b).
10. BEHRENDT, N., PLOUG, M., PATTHY, L., HOUEN, G., BLASI, F. and DANØ, K., The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J. biol. Chem., 266, 7842-7847 (1991).
11. BEHRENDT, N., RØNNE, E. and DANØ, K., Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J. biol. Chem., 271, 22885-22894 (1996).
12. 2 terminal amino acid sequence and glycosylation variants. J. biol. Chem., 265, 6453-6460 (1990).
13. BEHRENS, J., The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res. Treat., 24, 175-184 (1993).
14. BERGMAN, B.L., SCOTT, R.W., BAJPAI, A., WATTS, S. and BAKER, J., Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc. nat. Acad. Sci. (Wash.), 83, 996-1000 (1986).
15. BERKENPAS, M.B. and QUIGLEY, J.P., Transformation-dependent activation of urokinase-type plasminogen activator by a plasmin-independent mechanism: involvement of cell surface membranes. Proc. nat. Acad. Sci. (Wash.), 88, 7768-7772 (1991).
16. BESSER, D., VERDE, P., NAGAMINE, Y. and BLASI, F., Signal transduction and the u-PA/u-PAR system. Fibrinolysis, 10, 215-237 (1996).
17. BIANCHI, E., COHEN, R.L., DAI, A., THOR, A.T., SHUMAN, M.A. and SMITH, H.S., Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int. J. Cancer, 60, 597-603 (1995).
18. BIANCHI, E., COHEN, R.L., THOR, A.T., TODD, R.F., MIZZUKAMI, I.F., LAWRENCE, D.A., LJUNG, B.M., SHUMAN, M.A. and SMITH, H.S., The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res., 54, 861-866 (1994).
19. BIANCHI, E., FERRERO, E., FAZIOLI, F., MANGILI F., WANG, J., BENDER, J.R., BLASI, F. and PARDI, R., Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J. clin. Invest., 98, 1133-1141 (1996).
20. BINDAHL, A.K., HAMMOUD, M., SHI, W.M., Wu, S.Z., SAWAYA, R. and RAO, J.S., Prognostic significance of proteolytic enzymes in human brain tumors. J. Neurooncol., 22, 101-110 (1994).
21. 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J. exp. Med., 181, 1381-1390 (1995).
22. BOLON, I., GOUYER, V., DEVOUASSOUX, M., VANDERBUNDER, B., WERNERT, N., MORO, D., BRAMBILLA, C. and BRAMBILLA, E., Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Amer. J. Pathol. 147, 1298-1310 (1995).
23. BOTTERI, F.M., BALLMER-HOFER, K., RAJPUT, B. and NAGAMINE, Y., Disruption of cytoskeletal structures results in the induction of the urokinase-type plasminogen activator gene expression. J. biol. Chem., 265, 13327-13334 (1990).
24. BOUCHET, C., SPYRATOS, F., MARTIN, P.M., HACENE, K., GENTILE, A. and OGLOBINE, J., Prognostic value of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Brit. J. Cancer, 69, 398-405 (1994).
25. BRÜCKNER, A., FILDERMAN, A.E., KIRCHHEIMER, J.C., BINDER, B.R. and REMOLD, H.G., Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell line A549 and Calu-1. Cancer Res., 52, 3043-3047 (1992).
26. BRUNNER, G., SIMON, M.M. and KRAMER, M.D., Activation of pro-urokinase by the human T cell-associated serine proteinase HuTSP-1. FEBS Lett., 260, 141-144 (1990).
27. BRUNNER, G., VETTEL, U., JOBSTMANN, S., KRAMER, M.D. and SCHIRRMACHER, V., A T-cell-related proteinase expressed by T-lymphoma cell activates their endogenous pro-urokinase. Blood, 79, 2099-2106 (1992).
28. BUGGE, T.H., FLICK, M.J., DANTON, M.J., DAUGHERTY, C.C., RØMER, J., DANØ, K., CARMELIET, P., COLLEN, D. and DEGEN, J.L., Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. nat. Acad. Sci. (Wash.), 93, 5899-5904 (1996).
29. BUGGE, T.H., FLICK, M.J., DAUGHERTY, C.C. and DEGEN, J.L., Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Develop., 9, 794-807 (1995a).
30. BUGGE, T.H., SUH, T.T., FLICK, M.J., DAUGHERTY, C.C., RØMER, J., SOLBERG, H., ELLIS, DANØ, K. and DEGEN, J.L., The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. biol. Chem., 270, 16886-16894 (1995b).
31. BUØ, L., LYBERG, T., JØRGENSEN, L., JOHANSEN, H.T. and AASEN, A.O., Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. Acta pathol. microbiol. immunol. Scand., 101, 235-241 (1993).
32. BURRIDGE, K., FATH, K., KELLY, T., NUCKOLLS, G. and TURNER, C., Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Ann. Rev. Cell Biol., 4, 487-525 (1988).
33. BUSSO, N., MASUR, S.K., LAZEGA, D., WAXMAN, S. and OSSOWSKI, L., Induction of cell migration by pro-urokinase binding to its receptor: possible mechanisms for signal transduction in human epithelial cells. J. Cell Biol., 126, 259-270 (1994).
34. CAJOT, J.-F., BAMAT, J., BERGONZELLI, G.E., KRUITHOF, E.K.O., MEDCALF, R.L., TESTUZ, J. and SORDAT, B., Plasminogen activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc. nat. Acad. Sci. (Wash.), 87, 6939-6943 (1990).
35. CAJOT, J.-F., SCHLEUNING, W.-D., MEDCALF, R.L., BAMAT, J., TESTUZ, J., LIEBERMANN, L. and SORDAT, B., Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion. J. Cell Biol., 109, 915-925 (1989).
36. CAO, D., MIZUKAMI, I.F., GARNI-WAGNER, B.-A., KINDZELSKII, A.L., TODD, R.F., BOXER, L.A. and PETTY, H.R., Human urokinase-type plasminogen activator primes neutrophils for Superoxide union release. Possible roles of complement receptor type-3 and calcium. J. Immunol., 154, 1817-1829 (1995).
37. CARMELIET, P., SCHOOJANS, L., KIEKENS, L., REAM, B., DEGEN, J.L., BRONSON, R., DEVOS, R., VAN DEN ORD, J.O.J., COLLEN, D. and MULLIGAN, R.C., Physiological consequences of loss of plasminogen activator gene function in mice. Nature (Lond.), 368, 419-424 (1994).
38. CARMELIET, P., STASSEN, J.-M., SCHOOJANS, L., REAM, B., VAN DEN OORD, J.J., DE MOL, M., MULLIGAN, R.C. and COLLEN, D., Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J. clin. Invest., 92, 2756-2760 (1993).
39. CARRIERO, M.V., FRANCO, P., DEL VECCHIO, S., MASSA, O., BOTTI, G., D'AIUTO, G., STOPPELLI, M.P. and SALVATORE, M., Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res., 54, 5445-5454 (1994).
40. CASSLÉN, B., NORDENGREN, J., GUSTAVSSON, B., NILBERT, M. and LUND, L.R., Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor. J. clin. Endocrinol. Metab., 80, 2776-2784 (1995).
41. CHOONG, P.F.M., FERNØ. M., ÅKERMAN, M., WILLEN, H., LANGSTRØM, E., GUSTAFSON, P., ALVEGARD, T. and RYDHOLM, A. Urokinase-plasminogen activator levels and prognosis in 69 soft-tissue sarcomas. Int. J. Cancer, 69, 268-272 (1996).
42. 2-macroglobulin receptor in human breast carcinomas. Int. J. Cancer, 66, 441-452 (1996).
43. CIAMBRONE, G.J. and MCKEOWN-LONGO, P.J., Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells. J. Cell Biol., 111, 2183-2195 (1990).
44. CIAMBRONE, G.J. and MCKEOWN-LONGO, P.J., Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J. biol. Chem., 267, 13617-13622 (1992).
45. CLARK, E.A. and BRUGGE, J.S., Integrins and signal transduction pathways. Science, 268, 233-239 (1995).
46. CLAYMAN, G., WANG, S.W., NICOLSON, G.L., EL-NAGGAR, A., MAZAR, A., HENKIN, J., BLASI, F., GOEPFERT, H. and BOYD, D.D., Regulation of urokinase-type plasminogen activator expression in squamous cell carcinoma of the oral cavity. Int. J. Cancer. 54, 73-80 (1993).
47. CLEMMENSEN, I., LUND, L.R., CHRISTENSEN, L. and ANDREASEN, P.A., A tetranectin-related protein is produced and deposited in extracellular matrix by human embryonal fibroblasts. Europ. J. Biochem., 195, 735-741 (1991).
48. COHEN, R.L., XI, X.-P., CROWLEY, C.W., LUCAS, B.K., LEVINSON, A.D. and SHUMAN, M.A., Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood, 78, 479-487 (1991).
49. COLLEN, D., On the regulation of fibrinolysis. Thrombosis Haemostasis, 43, 77-89 (1980).
50. CONDEELIS, J., Life at the leading edge: the formation of cell protrusions. Ann. Rev. Cell Biol., 9, 411-444 (1993).
51. 2-macroglobulin in human U937 cells. FEBS Lett., 358, 73-78 (1995a).
52. 2-Macroglobulin receptor/LDL receptor related protein (LRP)-dependent internalization of the urokinase receptor. J. Cell Biol., 131, 1609-1622 (1995b).
53. 2-macroglobulin receptor. J. biol. Chem., 269, 17886-17892 (1994).
54. CROWLEY, C.W., COHEN, R.L., LUCAS, B.K., LIU, B.K., SHUMAN, M.A. and LEVINSON, A.D., Prevention of metastasis by inhibition of the urokinase receptor. Proc. nat. Acad. Sci. (Wash.), 90, 5021-5025 (1993).
55. CUBELLIS, M.V., ANDREASEN, P.A., RAGNO, P., MAYER, M., DANØ, K. and BLASI, F., Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc. nat. Acad. Sci. (Wash.), 86, 4828-4832 (1989).
56. CUBELLIS, M.V., NOLLI, M.L., CASSANI, G. and BLASI, F., Binding of single chain pro-urokinase to the urokinase receptor of human U937 cells. J. biol. Chem., 261, 15819-15822 (1986).
57. CUBELLIS, M.V., WUN, T.C. and BLASI, F., Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J., 9, 1079-1085 (1990).
58. DANØ, K., ANDREASEN, P.A., GRØNDAHL-HANSEN, K., KRISTENSEN, P., NIELSEN, L.S. and SKRIVER, L., Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44, 139-266 (1985).
59. DANØ, K., BEHRENDT, N., BRÜNNER, N., ELLIS, V., PLOUG, M. and PYKE, C., The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis, 8(Suppl. 1), 189-203 (1994).
60. DEAR, A.E. and MEDCALF, R.L., The cellular and molecular biology of plasminogen activator inhibitor type-2. Fibrinolysis, 9, 321-330 (1995).
61. DELBALDO, C., CUNNINGHAM, M., VASSALLI, J.-D. and SAPPINO, A.-P., Plasmin-catalysed proteolysis in colorectal neoplasia. Cancer Res., 55, 4688-4695 (1995).
62. DEL ROSSO, M., ANICHINI, E., PEDERSEN, N., BLASI, F., FIBBI, G., PUCCI, M. and RUGGIERO, M., Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. Biochem. biophys. Res. Comm., 190, 347-352 (1993).
63. DEL ROSSO, M., FIBBI, G., DINI, G., GRAPPONE, C., PUCCI, M., CALDINI, R., MAGNELLI, L., FIMIANI, M., LOTTI, T. and PANCONESI, E., Role of specific membrane receptors in urokinase-dependent migration of human keratinocytes. J. invest. Dermatol., 94, 310-316 (1990).
64. DEL ROSSO, M., FIBBI, G., PUCCI, M., DINI, G., GRAPPONE, C. and NOLLI, M.L., Modulation of surface-associated urokinase: binding, interiorizalion, delivery to lysosomes, and degradation in human keratinocytes. Exp. Cell Res., 193, 346-355 (1991).
65. DEL ROSSO, M., PEDERSEN, N., FIBBI, G., PUCCI, M., DINI, G., ANICHINI, E. and BLASI, F., Selective localization of receptors for urokinase aminoterminal fragment at substratum contact sites of an in vitro-established line of human epidermal cells. Exp. Cell Res., 203, 427-434 (1992).
66. DENG, G., CURRIDEN, S.A., WANG, S., ROSENBERG, S. and LOSKUTOFF, D.J., Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol., 134, 1563-1571 (1996).
67. DENG, G., ROYLE, G., SEIFFERT, D. and LOSKUTOFF, D.J., The PAI-1/ vitronectin interaction: two cats in a bag? Thrombosis Haemostasis, 74, 66-70 (1995).
68. DE VRIES, T.J., QUAX, P.H.A., DENIJN, M., VERRIJP, K.N., VERHEIJEN, J.H., VERSPAGET, H.W., WEIDLE, U.H., RUITER, D.J. and VAN MUIJEN, N.P., Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Amer. J. Pathol., 144, 70-81 (1994).
69. DEWERCHIN, M., NUFFELEN, A.V., WALLAYS, G., BOUCHE, A., MOONS, L., CARMELIET, P., MULLIGAN, R.C. and COLLEN, D., Generation and characterization of urokinase receptor-deficient mice. J. clin. Invest., 97, 870-878 (1996).
70. DONATE, L.E., GHERARDI, E., SRINIVASAN, N., SOWDHAMINI, R., APARICIO, S. and BLUNDELL, T.L., Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci., 3, 2378-2394 (1994).
71. DUFFY, M.J., Plasminogen activators and cancer. Blood Coagul. Fibrinolysis, 1, 681-687 (1990).
72. DUFFY, M.J., Urokinase-type plasminogen activator and malignancy. Fibrinolysis, 7, 295-302 (1993).
73. DUFFY, M.J., Proteases as prognostic markers in cancer. Clin. Cancer Res., 2, 613-618 (1996).
74. DUFFY, M.J., O'GRADY, P., DEVANEY, D., O'SIORAIN, L., FENNELLY, J.J. and LIJNEN, H.J., Urokinase-plasminogen activator, a marker for aggressive breast cancers. Cancer, 62, 531-533 (1988).
75. DUFFY, M.J., REILLY, D., MCDERMOTT, E., O'HIGGINS, N., FENNELLY, J.J. and ANDREASEN, P.A., Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer, 74, 2276-2280 (1994).
76. DUFFY, M.J., REILLY, D., NUGENT, A., MCDERMOTT, E., PAUL, C., FENNELLY, J.J. and O'IGGINS, N., Evaluation of proteolytic enzymes implicated in cancer metastasis as prognostic markers in breast cancer. Irish J. med. Sci., 161 (Suppl. 11), 49 (1992).
77. DUFFY, M.J., REILLY, D., O'SULLIVAN, C., O'HIGGINS, N., FENNELLY, J.J. and ANDREASEN, P.A., Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res., 50, 6827-6829 (1990).
78. DUGGAN, C., MAGUIRE, T., MCDERMOTT, E., O'HIGGINS, N., FENNELLY, J.J. and DUFFY, M.J., Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int. J. Cancer, 61, 597-600 (1995).
79. DUMLER, I., PETRI, T. and SCHLEUNING, W.-D., Interaction of urokinase-type plasminogen activator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett., 322, 37-40 (1993).
80. DUMLER, I., PETRI, T. and SCHLEUNING, W.-D., Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. FEBS Lett., 343, 103-106 (1994).
81. DUVAL-JOBE, C. and PARMELY, M.J., Regulation of plasminogen activation by human U937 promonocytic cells. J. biol. Chem., 269, 21353-21357 (1994).
82. DVORAK, H.F., BROWN, L.F., DETMAR, M. and DVORAK, A.M., Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Amer. J. Pathol., 146, 1029-1039 (1995).
83. EITZMAN, D.T., KRAUSS, J.C., SHEN, T., CUI, J. and GINSBURG, D., Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood, 87, 4718-4722 (1996).
84. ELLIS, V., BEHRENDT, N. and DANØ, K., Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J. biol Chem., 266, 12752-12758 (1991).
85. ELLIS, V., SCULLY, M.F. and KAKAR, V.V., Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J. biol. Chem., 264, 2184-2188 (1989).
86. ELLIS, V., WUN, T.-C., BEHRENDT, N., RØNNE, E. and DANØ, K., Inhibition of receptor-bound urokinase by plasminogen activator inhibitor. J. biol. Chem., 265, 9904-9908 (1990).
87. ESCOT, C., ZHAO, Y., PUECH, C. and ROCHEFORT, H., Cellular localization by in situ hybridization of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer. Breast Cancer Res., Treat., 38, 217-226 (1996).
88. ESPAÑA, F., ESTELLES, A., FERNANDEZ, P.J., GILABERT, J., SANCHEZ-CUENCA, J. and GRIFFIN, J.H., Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma. Thrombosis Haemostasis, 70, 989-994 (1993).
89. ESTREICHER, A., MÜHLHAUSER, J., CARPENTIER, J.-L., ORCI, L. and VASSALLI, J.-D., The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol., 111, 783-792 (1990).
90. EVANS, D.M. and LIN, P.L., Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Amer. Surg., 61, 692-697 (1995).
91. FALCONE, D.J., BORTH, W., MCCAFFREY, T.A., MATHEW, J. and MCADAM, K., Regulation of macrophage receptor-bound plasmin by autoproteolysis. J. biol. Chem., 269, 32660-32666 (1994).
92. FAZIOLI, F. and BLASI, F., Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol. Sci., 15, 25-29 (1994).
93. FELDING-HABERMANN, B. and CHERESH, D.A., Vitronectin and its receptors. Curr. Opin. Cell Biol., 5, 864-868 (1993).
94. FERNØ, M., BENDAHL, P.O., BORG, A., BRUNDELL, J., HIRSCHBERG, L., OLSSON, H. and KILLANDER, D., Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Europ. J. Cancer, 32A, 793-801 (1996).
95. FIBBI, G., ZICHE, M., MORBIDELLI, L., MAGNELLI, L. and DEL ROSSO, M., Interaction of urokinase with specific receptors stimulate mobilization of bovine adrenal capillary endothelial cells. Exp. Cell Res., 179, 385-395 (1988).
96. FOEKENS, J.A., BUESSECKER, F., PETERS, H.A., KRAINICK, U., VAN PUTTEN, W.L.J., LOOK, M.P., KLIJN, J.G.M. and KRAMER, M.D., Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res., 55, 1423-1427 (1995).
97. FOEKENS, J.A., SCHMITT, M., VAN PUTTEN, W.L.J., PETERS, H.A., BONTELBAL, M., JÄNICKE, F. and KLIJN, J.G.M., Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res., 52, 6101-6105 (1992).
98. FOEKENS, J.A., SCHMITT, M., VAN PUTTEN, W.L.J., PETERS, H.A., KRAMER, M.D., JÄNICKE, F. and KLIJN, J.G.M., Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J. clin. Oncol., 12, 1648-1658 (1994).
99. FOLKMAN, J., Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature (Med.), 1, 27-31 (1995).
100. FRIXEN, H. and NAGAMINE, Y., Stimulation of urokinase-type plasminogen activator expression by blockage of E-cadherin-dependent cell-cell adhesion. Cancer Res., 53, 3618-3623 (1993).
101. GANESH, S., SIER, C.F.M., GRIFFIOEN, G., VLOEDGRAVEN, H., DE BOER, A., WELWAART, K., VAN DE VELDE, C., VAN KRIEKEN, J., VERHEIJEN, J., LAMERS, C. and VERSPAGET, H.W., Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 54, 4065-4071 (1994a).
102. GANESH, S., SIER, C.F.M., HEERDING, M.H., GRIFFIOEN, G., LAMERS, C. and VERSPAGET, H.W., Urokinase receptor and colorectal cancer survival. Lancet, 344, 401-402 (1994b).
103. GEIGER, B. and AYALON, O., Cadherins. Ann. Rev. Cell. Biol. 8, 307-332 (1992).
104. GINSBERG, M.H., Du, X. and PLOW, E.F., Inside-out integrin signalling. Curr. Opin. Cell Bioi., 4, 766-771 (1992).
105. GLADSON, C.L., PIJUAN-THOMPSON, V., OLMAN, M.A., GILLESPIE, G.Y. and YACOUD, I.Z., Upregulation of urokinase and urokinase receptor genes in malignant astrocytoma. Amer. J. Pathol., 146, 1150-1160 (1995).
106. GLASS, W.F., RADNIK, R.A., GARONI, J.A. and KREISBERG, J.I., Urokinase-dependent adhesion loss and shape change after cyclic adenosine monophosphate elevation in cultured rat mesangiai cells. J. clin. Invest., 82, 1992-2000 (1988).
107. GOODSON, R.J., DOYLE, M.V., KAUFMAN, S.E. and ROSENBERG, S., High affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. nat. Acad. Sci. (Wash.), 91, 7129-7133 (1994).
108. GORETZKI, L., SCHMITT, M., MANN, K., CALVETE, J., CHUCHOLOWSKI, N., KRAMER, M., GÜNZLER, W.A., JÄNICKE, F. and GRAEF, H., Effective activation of the pro-enzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett., 297, 112-118 (1992).
109. GRØNDAHL-HANSEN, J., CHRISTENSEN, I.J., ROSENQUIST, C., BRÜNNER, N., MOURIDSEN, H.T., DANØ, K. and BLICHERT-TOFT, M., High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53, 2513-2521 (1993).
110. GRØNDAHL-HANSEN, J., PETERS, H.A., VAN PUTTEN, W.L.J., LOOK, M.P., PAPPOT, H., RØNNE, E., DANØ, K., KLIJN, J.G.H., BRÜNNER, N. and FOEKENS, J.A., Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin. Cancer Res., 1, 1079-1087 (1995).
111. GRØNDAHL-HANSEN, J., RALFSKIAER, E., KIRKEBY, L.T., KRISTENSEN, P., LUND, L.R. and DANØ, K., Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinoma of the colon in humans. Amer. J. Pathol., 138, 111-117 (1991).
112. GUDEWICZ, P.W. and GILBOA, N., Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem. biophys. Res. Comm., 147, 1176-1181 (1987).
113. GYETKO, M.R., TODD, R.F., WILKINSON, C.C. and SITRIN, R.G., The urokinase receptor is required for human monocyte chemotaxis in vitro. J. clin. Invest., 93, 1380-1387 (1994).
114. HANSEN, S., BEHRENDT, N., DANØ, K. and KRISTENSEN, P., Localization of urokinase-type plasminogen activator receptor on U937 cells: phorbol ester PMA induces heterogeneity. Exp. Cell Res., 187, 255-262 (1990).
115. HARRIS, A.L., Fox, S., LEEK, R., ZHANG, H., SCOTT, P., BICKNELL, R. and GATTER, K., Breast cancer angiogenesis. Therapy target and prognostic factor. Europ. J. Cancer, 31A, 831-832 (1995).
116. HASUI, Y., MARUTSUKA, K., SUZUMIYA, J., KITADA, S., OSDA, Y. and SUMIYOSHI, A., The content of urokinase-type plasminogen activator as a prognostic factor in bladder cancer. Int. J. Cancer, 50, 871-873 (1992).
117. HE, C.J., REBIBOU, J.M., PERALDI, M.N., MEULDERS, Q. and RONDEAU, E., Growth factor-like effect of urokinase-type plasminogen activator in human renal cells. Biochem. biophys. Res. Comm., 176, 1408-1416 (1991).
118. HÉBERT, C.A. and BAKER, J., Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J. Cell Biol., 106, 1241-1247 (1988).
119. HEEGAARD, C.W., SIMONSEN, A.C.W., OKA, K., KJØLLER, L., CHRISTENSEN, A., MADSEN, B., ELLGAARD, L., CHAN, L. and ANDREASEN, P.A., Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator/type-1 plasminogen activator inhibitor complex. J. biol. Chem., 270, 20855-20861 (1995).
120. HEISS, M.M., ALLGAYER, H., GRUETZNER, K.U., FUNKE, I., BABIC, R., JAUCH, K.-W. and SCHILDBERG, F.W., Individual development and u-PA receptor expression of disseminated tumour cells in bone marrow: a reference to early disease in solid cancer. Nature (Med.), 1, 1035-1038 (1995).
121. HEMBROUGH, T.A., KRALOVICH, LI, L. and GONIAS, S.L., Cytokeratin 8 released from breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem. J., 317, 763-769 (1996).
122. HESS, S., KANSE, S.M., KOST, C. and PREISSNER, K.T., The versatility of adhesion receptor ligands in haemostasis: morpho-regulatory functions of vitronectin. Thrombosis Haemostasis, 74, 258-265 (1995).
123. HIGGINS, P.J., RYAN, M.P. and PROVIDENCE, K.M., Induced expression of p52 (PAI-1) in normal kidney cells by the microfilament-disrupting agent cytochalasin D. J. cell. Physiol., 159, 187-195 (1994).
124. HIGGINS, P.J., RYAN, M.P., ZEHEB, R., GELEHRTER, T.D. and CHAUDHARI, P., p52 induction by cytochalasin D in rat kidney fibroblasts: homologies between p52 and plasminogen activator type-1. J. cell. Physiol., 143, 321-329 (1990).
125. HILDENBRAND, R., DILGER, I., HORLIN, A. and STUTTE, H.J., Urokinase and macrophages in tumor angiogenesis. Brit. J. Cancer, 72, 818-823 (1995).
126. HOFMANN, R., LEHMER, A., BURESCH, M., HARTUNG, R. and ULM, K., Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer, 78, 487-492 (1996).
127. HOLLAS, W., BLASI, F. and BOYD, D., Role of urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res., 51, 3690-3695 (1991).
128. HOLST-HANSEN, C., JOHANNESSEN, B., HØYER-HANSEN, G., RØMER, J., ELLIS, V. and BRÜNNER, N., Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin. exp. Metastasis, 14, 297-307 (1996).
129. HOWELL, A.L., HUNT, J.A., JAMES, T.W., MAZAR, A., HENKIN, J. and ZACHARSKI, L.R., Urokinase inhibits HL-60 proliferation in vitro. Blood Coagul. Fibrinolysis, 5, 445-453 (1994).
130. HØYER-HANSEN, G., RØNNE, E., SOLBERG, H., BEHRENDT, N., PLOUG, M., LUND, L.R., ELLIS, V. and DANØ, K., Urokinase plasminogen activator cleaves its cell surface receptor, releasing the ligand binding domain. J. biol. Chem., 267, 18224-18229 (1992).
131. HYNES, R.O., Integrins: versatility, modulation, and signalling in cell adhesion. Cell, 69, 11-25 (1992).
132. ICHINOSE, A., FUJIKAWA, K. and SUYAMA, T., The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J. biol. Chem., 261, 3486-3489 (1986).
133. JÄNICKE, F., SCHMITT, M., HAFTER, R., HOLLRIEDER, A., BABIC, R., ULM, K., GÖSSNER, W. and GRAEFF, H., Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis, 4, 69-78 (1990).
134. JÄNICKE, F., SCHMITT, M., PACHE, L., ULM, K., HARBECK, N., HÖFLER, H. and GRAEFF, H., Urokinase plasminogen activator (u-PA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat., 24, 195-208 (1993).
135. JANKUN, J., MERRICK, H.W. and GOLDBLATT, P.J., Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J. cell. Biochem., 53, 135-144 (1993).
136. JARRARD, D.F., HANSEN, N.M., PATAI, B. and RUKSTALIS, D.B., Urokinase plasminogen activator is necessary but not sufficient for prostate cancer cell invasion. Invasion Metastasis, 15, 34-45 (1995).
137. JENSEN, P.H., CHRISTENSEN, E.I., EBBESEN, P., GLIEMANN, J. and ANDREASEN, P.A., Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells. Cell Regul., 1, 1043-1056 (1990).
138. JENSEN, P.J. and WHEELOCK, M.J., Regulation of urokinase plasminogen activator localization in keratinocytes by calcium ion and E-cadherin. Exp. Cell Res., 202, 190-198 (1992).
139. KANSE, S.M., KOST, C., WILHELM, O.G., ANDREASEN, P.A. and PREISSNER, K.T., The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res., 224, 344-353 (1996).
140. KARIKÓ. K., KUO, A., BOYD, D., OKADA, S.S., CINES, D.B. and BARNATHAN, E.S., Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res., 53, 3109-3117 (1993).
141. KIM, D.-H., IIJAMA, H., GOTO, K., SAKAI, J., ISHII, H., KIM, H.-J., SUZUKI, H., KONDO, H., SAEKI, S. and YAMAMOTO, T., Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J. biol. Chem., 271, 8373-8380 (1996).
142. KIRCHHEIMER, J.C. and REMOLD, H.G., Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. J. Immunol., 143, 2634-2639 (1989).
143. 2-macroglobulin receptor and urokinase receptor expression. Mol. cell. Endocrinoi., 109, 209-217 (1995).
144. KJØLLER, L., KANSE, S., KIRKEGAARD, T., RODENBURG, K.W., RØNNE, E., GOODMANN, S.L., PREISSNER, K.T., OSSOWSKI, L. and ANDREASEN, P.A., Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. 232, 420-429 (1997).
145. KOBAYASHI, H., FUJIE, M., SHINOHARA, H., OHI, H., SUGIMURA, M. and TERAO, T. Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells. Int. J. Cancer, 57, 378-384 (1994a).
146. KOBAYASHI, H., FUJISHIRO, S. and TERAO, T., Impact of urokinase-type plasminogen activator and its inhibitor type-1 on prognosis in cervical cancer of the uterus. Cancer Res.. 54, 6539-6548 (1994b).
147. KOBAYASHI, H., GOTOH, J., FUJIE, M., SHINOHARA, H., MINIWA, N. and TERAO, T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer, 57, 727-733 (1994c).
148. KOBAYASHI, H., GOTOH, J., HIRASHIMA, Y., FUJIE, M., SUGINO, D. and TERAO, T. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J. biol. Chem., 270, 8361-8366 (1995).
149. KOBAYASHI, H., MONIWA, N., SUGIMURA, M., SHIOHARA, H., OHI, H. and TERAO, T. Effects of membrane-associated cathepsin B on the activation of receptor-bound pro-urokinase and subsequent invasion of reconstituted basement membranes. Biochim. biophys. Acta, 1178, 55-62 (1993a).
150. KOBAYASHI, H., OHI, H., SHINOHARA, H., SUGIMURA, M., FUJIE, T., TERAO, T., SCHMITT, M., GORETZKI, L., CHUCHOLOWSKI, N. JÄNICKE, F., and GRAEF, H. Saturation of tumor cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted
151. KOBAYASHI, H., SCHMITT, M., GORETZKI, L., CHUCHOLOWSKI, N., CALVETE, J., KRAMER, M., GÜNZLER, W.A., JÄNICKE, F. and GRAEFF, H., Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J. biol. Chem., 266, 5147-5152 (1991).
152. KOBAYASHI, H., SHINOHARA, H., OHI, H., SUGIMLIRA, M., TERAO, T. and FUJIE, M., Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion. Clin. exp. Metastasis, 12, 117-128 (1994d).
153. KOBAYASHI, H., SHINOHARA, H., TAKEUCHI, K., ITOH, M., FUJIE, M., SATOH, M. and TERAO, T. Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. Cancer Res., 54, 844-849 (1994e).
154. KOIVUNEN, E., HUHTALA, M.-L. and STENMAN, U.-H., Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J. biol. Chem., 264, 14095-14099 (1989).
155. KOOK, Y.H., ADAMSKI, J., ZELENT, A. and OSSOWSKI, L., The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J., 13, 3983-3991 (1994).
156. 2-macroglobulin receptor mediates cellular uptake of prourokinase. J. biol. Chem., 268, 21862-21867 (1993).
157. KRAMER, M.D., SPRING, H., TODD, R.F. and VETTEL, U., Urokinase-type plasminogen activator enhances invasion of human T cells (Jurkat) into a fibrin matrix. J. Leukocyte Biol., 56, 110-116 (1994).
158. KRÄTZSCHMAR, J., HAENDLER, B., KOJIMA, S., RIFKIN, D.B. and SCHLEUNIG, W.D., Bovine urokinase-type plasminogen activator and its receptor: cloning and induction by retinoic acid. Gene, 125, 177-183 (1993).
159. KRISTENSEN, P., ERIKSEN, J., BLASI, F. and DANØ, K., Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J. Cell Biol., 115, 1763-1771 (1991).
160. KRISTENSEN, P., PYKE, C., LUND, L.R., ANDREASEN, P.A. and DANØ, K., Plasminogen activator inhibitor type-1 in Lewis lung carcinoma. Histochemistry, 93, 559-566 (1990).
161. KUHN, W., PACHE, L., SCHMALFELDT, B., DETTMAR, P., SCHMITT, M., JÄNICKE, F. and GRAEFF, H., Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical and platinum-based chemotherapy. Gynecol. Oncol., 55, 401-409 (1994).
162. LARSSON, L.-I., Peptide immunocytochemistry. Progr. Histochem. Cytochem., 13, 1-85 (1981).
163. LAU, H.K. and KIM, M., Soluble urokinase receptor from fibrosarcoma HT-1080 cells. Blood Coagul. Fibrinolysis, 5, 473-478 (1994).
164. LAUFFENBURGER, D.A. and HORWITZ, A.F., Cell migration: a physically integrated molecular process. Cell. 84, 359-369 (1996).
165. LAUG, W.E., CAO. X.R., Yu, Y.B., SHIMADA, H. and KRUITHOF, E.K., Inhibition of invasion of HT-1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res., 53, 6051-6057 (1993).
166. LEE, J., ISHIHARA, A. and JACOBSON, K., How do cells move along surfaces? Trends Cell Biol., 3, 366-370 (1993).
167. 1 cells. Nucleic Acids Res., 21, 3365-3372 (1993).
168. LI, C., LIU, J.-N. and GUREWICH, V., Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction. J. biol. Chem., 270, 30282-30285 (1995).
169. LIND, S.E. and SMITH, C.J., Actin accelerates plasmin generation by tissue plasminogen activator. J. biol. Chem., 266, 17673-17678 (1991).
170. LIOTTA, L.A., STEEG, P.S. and STETLER-STEVENSON, W.G., Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-336 (1991).
171. LIU, G., SHUMAN, M.A. and COHEN, R.L., Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer, 60, 501-506 (1995).
172. LOSKUTOFF, D.J., SAWDEY, M., KEETON, M. and SCHEIDERMAN, J., Regulation of PAI-1 gene expression in vivo. Thrombosis Haemostasis. 70, 135-137 (1993).
173. LU, H., MABILAT, C., YEH, P., GUITTON, J.D., LI, H., POUCHELET, M., SHOEVAERT, D., LEGRAND, Y., SORIA, J. and SORIA, C., Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett., 380, 21-24 (1996).
174. LU, H., YEH, P., GLUTTON, J.D., MABILAT, C., DESANLIS, F., MAURY, I., LEORAND, Y., SORIA, J. and SIRIA, C., Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett., 356, 56-59 (1994).
175. LUPARELLO, C. and DEL ROSSO, M., In vitro anti-proliferative and anti-invasive role of amino-terminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells. Europ. J. Cancer. 32A, 702-707 (1996).
176. MAGDOLEN, V., RETTENBERGER, P., KOPPITZ, M., GORETZKI, L., KESSLER, H., WEIDLE, U.H., KÖNIG, B., GRAEFF, H., SCHMITT, M. and WILHELM, O., Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Europ. J. Biochem., 237, 743-751 (1996).
177. MARCOTTE, P.A., KOZAN, I.M., DORWIN, S.A. and RYAN, J.M., The matrix metalloproteinase Pump-1 catalyzes formation of low molecular weight (pro)urokinase in cultures of normal human kidney cells. J. biol. Chem., 267, 13803-13806 (1992).
178. MARS, W.M., ZARNEGAR, R. and MICHAELOPOULOS, G.K., Activation of hepatocyte growth factor by the plasminogen activators u-PA and t-PA. Amer. J. Pathol., 143, 949-958 (1993).
179. MAWATARI, O., OKAMURA, K., MATSUDA, T., HAMANAKA, R., MIZOGUCHI, H., HIGASHIO, K., KOHNO, K. and KUWANO, M., Tumor necrosis factor and epidermal growth factor modulate migration of human microvascular endothelial cells and production of tissue-type plasminogen activator and its inhibitor. Exp. Cell Res., 192, 574-580 (1991).
180. MCGUIRE, P.G. and ALEXANDER, S.M., Inhibition of urokinase synthesis and cell surface binding alters the motile behaviour of embryonic endocardial-derived mesenchymal cells in vitro. Development, 118, 931-939 (1993).
181. MEISSAUER, A., KRAMER, M.D., HOFMANN, M., ERKELL, L.J., JACOB, E., SCHIRRMACHER, V. and BRUNNER, G., Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. Exp. Cell Res., 192, 453-459 (1991).
182. MIGNATTI, P. and RIFKIN, D.B., Biology and biochemistry of proteinases in tumor invasion. Physiol Rev., 73, 161-195 (1993).
183. MIGNATTI, P., ROBBINS, E. and RIFKIN, D.B., Tumor invasion through the human amniotic membrane. Requirement for a proteinase cascade. Cell, 47, 487-498 (1986).
184. MILLER, S.J., JENSEN, P.J., DZUBOW, L.M. and LAZARUS, G.S., Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. J. invest. Dermatol., 98, 351-358 (1992).
185. MIN, H.Y., DOYLE, L.V., VITT, C.R., ZANDONELLA, C.L., STRATTON-THOMAS, J.R., SHUMAN, M.A. and ROSENBERG, S., Urokinase receptor antagonists inhibit angiogenesis and primary growth in syngeneic mice. Cancer Res., 56, 2428-2433 (1996).
186. 2-macroglobulin receptor and epithelial glycoprotein-330. Two giant receptors mediating endocytosis of multiple ligands. Biochim. biophys. Acta, 1197, 197-213 (1994).
187. 2-macroglobulin receptor containing a cluster of eight complement-type repeats. J. biol. Chem., 268, 13691-13696 (1993a),
188. MOESTRUP, S.K., NIELSEN, S., ANDREASEN, P.A., JØRGENSEN, K.E., NYKJAER, A., RØIGAARD, H., GLIEMANN, J. and CHRISTENSEN, E.I., Epithelial glycoprotein 330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J. biol. Chem., 268, 16564-16570 (1993b).
189. MOHANAM, S., SAWAYA, R., MCCUTCHEON, I., ALI-OSMAN, F., BOYD, D. and RAO, J.S., Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res., 53, 4143-4147 (1993).
190. MOHANAM, S., SAWAYA, R., YAMAMOTO, M., BRUNER, J.M., NICHOLSON, G.L. and RAO, J.S., Proteolysis and invasiveness of brain tumors. Role of urokinase-type plasminogen activator receptor. J. Neurooncol., 22, 153-160 (1994).
191. MØLLER, L.B., PLOUG, M. and BLASI, F., Structural requirements for glycosyl-phosphatidyl-inositol-anchor attachment in the cellular receptor for urokinase plasminogen activator. Europ. J. Biochem., 208, 493-500 (1992).
192. MONTESANO, R., PEPPER, M.S., MÖHLE-STEINLEIN, U., RISAU, W., WAGNER, E.F. and ORCI, L., Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell. 62, 435-445 (1990).
193. MONTESANO, R., PEPPER, M.S., VASSALLI, J.-D. and ORCI, L., Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors. J. cell. Physiol., 132, 509-516 (1987).
194. MORIMOTO, K., MISHIMA, H., NISHIDA, T. and OTORI, T., Role of urokinase type plasminogen activator (u-PA) incomeal epithelial migration. Thrombosis Haemostasasis, 69, 387-391 (1993).
195. MOROIANU, N., FETT, J.W., RIORDAN, J.F. and VALLEE, B.L., Actin is a surface component of calf pulmonary artery endothelial cells in culture. Proc. nat. Acad. Sci. (Wash.), 90, 3815-3819 (1993).
196. MOSER, T.L., ENGHILD, J.J., PIZZO, S.V. and STACK, M.S., Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem. J., 307, 867-873 (1995).
197. MUELLER, B.M., YU, Y.B. and LAUG, W.E., Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc. nat. Acad. Sci. (Wash.), 92, 205-209 (1995).
198. MULCAHY, H.E., DUFFY, M.J., GIBBONS, P., MCCARTHY, P., PARFREY, N.A., O'DONOGHUE, D.P. and SHEAHAN, K., Urokinase-type plasminogen activator and outcome in Duke's B colorectal cancer. Lancet, 344, 583-584 (1994).
199. MYÖHÄNEN, H.T., STEPHENS, R.W., HEDMAN, K., TAPIOVAARA, H., RØNNE, E., HØYER-HANSEN, G., DANØ, K. and VAHERI, A., Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J. Histochem. Cytochem., 41, 1291-1301 (1993).
200. NAGAYAMA, M., SATO, A., HAYAKAWA, H., URANO. T., TAKADA, Y. and TAKADA, A., Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer, 73, 1398-1405 (1994).
201. NAGY, J.A., BROWN, L.F., SENGER, D.R., LANIR, N., VAN DE WATER, L., DVORAK, A.M. and DVORAK, H.F., Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim. biophys. Acta, 948, 305-326 (1988).
202. NAITOH, H., EGUCHI, Y., UEYAMA, H., KODAMA, M. and HATTORI, T., Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer. Jpn J. Cancer Res., 86, 48-56 (1995).
203. NALDINI, L., TAMAGNONE, L., VIGNA, E., SACHS, M., HARTMANN, G., BIRCHMEIER, W., DAIKUHARA, Y., TSUBOUCHI, H., BLASI, F. and COMOGLIO, P.M., Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J., 11, 4825-4833 (1992).
204. NEKARDA, H., SIEWERT, J., SCHMITT, M. and ULM, K., Tumor-associated proteolytic factors u-PA and PAI-1 and survival in totally resected gastric cancer. Lancet, 343, 117 (1994).
205. NIELSEN, B.S., SEHESTED, M., TIMSHEL, S., PYKE, C. and DANØ. K., Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab. Invest., 74, 168-177 (1996).
206. NOVAK, S., HIESBERGER, T., SCHNEIDER, W.J. and NIMPF, J., A new low density lipoprotein receptor homologue with 8 ligand binding repeats in brain of chicken and mouse. J. biol. Chem., 271, 11732-11736 (1996).
207. NUSRAT, A.R. and CHAPMAN, H.A., An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J. clin. Invest., 87, 1091-1097 (1991).
208. NYKJAER, A., CONESE, M., CHRISTENSEN, E.I., OLSON, D., CREMONA, O., GLIEMANN, J. and BLASI, F., Recycling of the urokinase receptor upon internalization of uPA:serpin complexes. EMBO J. (1997) (In press).
209. 2-macroglobulin receptor/low density lipoprotein receptor-related protein. J. biol. Chem., 270, 25668-25676 (1994a).
210. NYKJAER, A., MØLLER, B., TODD, R.F., CHRISTENSEN, T., ANDREASEN, P.A., GLIEMANN, J. and PETERSEN, C.M., Urokinase receptor. An activation antigen in human lymphocytes. J. Immunol., 152, 505-516 (1994b).
211. NYKJAER, A., MUNCK PETERSEN, C., MØLLER, B., ANDREASEN, P.A. and GLIEMANN, J., Identification and characterization of urokinase receptors in natural killer cells and T-cell-derived lymphokine activated killer cells. FEBS Lett., 300, 13-17 (1992a).
212. 2-macroglobulin receptor mediates cellular degradation of urokinase receptor bound complexes. J. biol. Chem., 267, 14543-14546 (1992b).
213. ODEKON, L.E., BLASI, F. and RIFKIN, D.B., Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J. cell. Physiol., 158, 398-407 (1994).
214. ODEKON, L.E., SATO, Y. and RIFKIN, D.B., Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J. cell. Physiol., 150, 258-263 (1992).
215. OHKURA, N., INOUE, S., IKEDA, K. and HAYASHI, K., The two subunits of a phospholipase A2 inhibitor from the plasma Thailand cobra having structural similarity to urokinase-type plasminogen activator receptor and LY-6 related proteins. Biochem. biophys. Res. Comm., 204, 1212-1218 (1994).
216. OHTANI, H., PYKE, C., DANØ, K. and NAGURA, H., Expression of urokinase receptor in various stromal-cell populations in human colon cancer. Immunoelectron microscopal analysis. Int. J. Cancer, 62, 691-696 (1995).
217. OKA, T., ISHIDA, T., NISHINO, T. and SUGIMACHI, K., Immunohistochemical evidence for urokinase plasminogen activator in primary and metastatic tumors of pulmonary carcinoma. Cancer Res., 51, 3522-3525 (1991).
218. OKADA, S.S., TOMASZEWSKI, J.E. and BARNATHAN, E.S., Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro. Exp. Cell Res., 217, 180-187 (1995).
219. OLSON, D., PÖLLÄNEN, J., HØYER-HANSEN, G., RØNNE, E., SAKAGUCHI, K., WUN, T.-C., APPELLA, E., DANØ, K. and BLASI, F., Internalizalion of the urokinase:plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J. biol. Chem., 267, 9129-9133 (1992).
220. O'REILLY, M.S., HOLGREN, L., CHEN, C. and FOLKMAN, J., Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature (Med.), 2, 689-692 (1996).
221. O'REILLY, M.S., HOLGREN, L., SHING, Y., CHEN, C., ROSENTHAL, R.A., MOSES, M., LANE, W.S., CAO, Y., SAGE, E.H. and FOLKMAN, J., Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315-328 (1994).
222. ORNSTEIN, D.L., ZACHARSKI, L.R., MEMOLI, V.A., KISIEL, W., KUDRYK, B.J., HUNT, J., ROUSSEAU, G. and STUMP, D.C., Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. Cancer, 68, 1061-1067 (1991).
223. OSSOWSKI, L., Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chicken embryo. Cell, 52, 321-328 (1988a).
224. OSSOWSKI, L., In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J. Cell Biol., 107, 2437-2445 (1988b).
225. OSSOWSKI, L., Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res., 52, 6754-6760 (1992).
226. OSSOWSKI, L., CLUNIE, G., MASUCCI, M.-T. and BLASI, F., In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol., 115, 1107-1112 (1991a).
227. OSSOWSKI, L., QUIGLEY, J.P., KELLERMAN, G.M. and REICH, E., Fibrinolysis associated with oncogenic transformation. Requirement of plasminogen for correlated changes in cellular morphology, colony formation in agar, and cell migration. J. exp. Med., 138, 1056-1064 (1973).
228. OSSOWSKI, L. and REICH, E., Experimental model for quantitative study of metastasis. Cancer Res., 40, 2300-2309 (1983a).
229. OSSOWSKI, L. and REICH, E., Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35, 611-619 (1983b).
230. OSSOWSKI, L., RUSSO-PAYNE, H. and WILSON, E.L., Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res., 51, 274-281 (1991b).
231. PEDERSEN, H., BRÜNNER, N., FRANCIS, D., ØSTERLIND, K., RØNNE, E., HANSEN, H.H., DANØ, K. and GRØNDAHL-HANSEN, J., Prognostic impact of urokinase, urokinase receptor and type-1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54, 4671-4675 (1994a).
232. PEDERSEN, H., GRØNDAHL-HANSEN, J., FRANCIS, D., ØSTERLIND, K., HANSEN, H.H., DANØ, K. and BRÜNNER, N., Urokinase and plasminogen activator inhibitor type-1 in pulmonary adenocarcinoma. Cancer Res., 54, 120-123 (1994b).
233. PEDERSEN, N., SCHMITT, M., RØNNE, E., NICOLETTI, M.I., HØYER-HANSEN, G., CONESE, M., GIAVAZZI, R., DANØ, K., KUHN, W., JÄNICKE, F. and BLASI, F., A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J. clin. Invest., 92, 2160-2167 (1993).
234. PEPPER, M.S., MATSUMOTO, K., NAKAMURA, T., ORCI, L. and MONTESANO, R., Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J. biol. Chem., 267, 20493-20496 (1992).
235. PEPPER, M.S. and MONTESANO, R., Proteolytic balance and capillary morphogenesis. Cell Differentiation Develop., 32, 319-327 (1990).
236. PEPPER, M.S., SAPPING, A.-P., STÖCKLIN, R., MONTESANO, R., ORCI, L. and VASSALLI, J.-D., Upregulation of urokinase receptor expression on migrating endothelial cells. J. Cell Biol., 122, 673-684 (1993).
237. 1. Amer. J. Pathol., 149, 923-931 (1996).
238. PLOUG, M. and ELLIS, V., Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom α-neurotoxins. FEBS Lett., 349, 163-168 (1994).
239. PLOUG, M., ELLIS, V. and DANØ, K., Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1naphtalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry, 33, 8991-8997 (1994).
240. 2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J. biol. Chem., 268, 17539-17546 (1993).
241. PLOUG, M., RAHBEK-NIELSEN, H., ELLIS, V., ROEPSTORFF, P. and DANØ, K., Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. Biochemistry, 34, 12524-12534 (1995).
242. PLOUG, M., RØNNE, E., BEHRENDT, N., JENSEN, A.L., BLASI, F. and DANØ, K., Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidyl inositol. J. biol. Chem., 266, 1926-1933 (1991).
243. PLOW, E.F. and MILES, L.A., Plasminogen receptors in the mediation of pericellular proteolysis. Cell Differentiation Develop., 32, 293-298 (1990).
244. PÖLLÄNEN, J., The N-terminal domain of human urokinase receptor contains two distinct regions critical for ligand recognition. Blood, 82, 2719-2729 (1993).
245. PÖLLÄNEN, J., HEDMAN, K., NIELSEN, L.S., DANØ, K. and VAHERI, A., Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J. Cell Biol., 106, 87-95 (1988).
246. PÖLLÄNEN, J., SAKSELA, O., SALONEN, E.-M., ANDREASEN, P.A., NIELSEN, L.S., DANØ, K. and VAHERI, A., Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J. Cell Biol., 104, 1085-1096 (1987).
247. PÖLLÄNEN, J., STEPHENS, R.W. and VAHERI, A., Directed plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res., 57, 273-328 (1991).
248. PÖLLÄNEN, J., VAHERI, A., TAPIOVAARA, H., RILEY, E., BERTRAM, K., WOODROW, G. and STEPHENS, R.W., Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor. Proc. nat. Acad. Sci. (Wash.), 87, 2230-2234 (1990).
249. POTEMPA, J., KORZUS, E. and TRAVIS, J., The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. biol. Chem., 269, 15957-15960 (1994).
250. PYKE, C., ERIKSEN, J., SOLBERG, H., NIELSEN, B.S., KRISTENSEN, P., LUND, L.R. and DANØ, K., An alternatively spliced variant for the human receptor for urokinase plasminogen activator. FEBS Lett., 326, 69-74 (1993a).
251. PYKE, C., GRAEM, N., RALFKIAER, E., RØNNE, E., HØYER-HANSEN, G., BRÜNNER, N. and DANØ, K., Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinomas. Cancer Res., 53, 1911-1915 (1993b).
252. PYKE, C., KRISTENSEN, P., RALFKIAER, E., ERIKSEN, J. and DANØ, K., The plasminogen activation system in human colon cancer. Messenger RNA for the inhibitor PAI-1 is located in endothelial cells of tumor stroma. Cancer Res., 51, 4067-4071 (1991a).
253. PYKE, C., KRISTENSEN, P., RALFKIAER, E., GRØNDAHL-HANSEN, J., ERIKSEN, J., BLASI, F. and DANØ, K., Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Amer. J. Pathol. 138, 1059-1067 (1991b).
254. PYKE, C., RALFKIAER, E., RØNNE, E., HØYER-HANSEN, G., KIRKEBY, L. and DANØ, K., Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology, 24, 131-138 (1994).
255. PYKE, C., SALO, S., RALFKIAER, E., RØMER, J., DANØ. K. and TRYGGVASON, K., Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res., 55, 4132-4139 (1995).
256. QUATTRONE, A., FIBBI, G., ANICHINI, E., PUCCI, M., ZAMPERINI, A., CAPACCIOLI, S. and DEL ROSSO, M., Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res., 55, 90-95 (1995).
257. QUAX, P.H.A., BOXMAN, I.L.A., VAN KRSTEREN, C.A.M., VERHEIJEN, J.H. and PONEC, M., Plasminogen activators are involved in keratinocyte and fibroblast migration in wounded cultures in vitro. Fibrinolysis, 8, 221-228 (1994).
258. QUAX, P.H.A., PEDERSEN, N., MASUCCI, M.T., WEENING-VERHOEFF, E.J., DANØ, K., VERHEIJEN, J.H. and BLASI, F., Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul., 2, 793-803 (1991a).
259. QUAX, P.H.A., VAN MUIJEN, G.N.P., WEENING-VERHOEFF, E.J., LUND, L.R., DANØ, K., RUITER, D.J. and VERHEIJEN, J.H., Metastatic behaviour of human melanoma cell lines in nude mice correlated with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J. Cell Biol., 115, 191-199 (1991b).
260. RABBANI, S.A., DESJARDIN, J., BELL, A.W., BANVILLE, D., MAZAR, A., HENKIN, J. and GOLTZMAN, D., An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem. biophys. Res. Comm., 173, 1058-1064 (1990).
261. RABBANI, S.A., MAZAR, A.P., BERNIER, S.M., HAQ, M., BOLIVAR, I., HENKIN, J. and GOLTZMAN, D., Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J. biol. Chem., 267, 14151-14156 (1992).
262. RAGNO, P., MONTUORI, N. and ROSSI, G., Urokinase-type plasminogen activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen activator-receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen activator inhibitor complexes with the cell surface. Europ. J. Biochem., 233, 514-519 (1995).
263. RAO, J.S., STECK, P.A., TOFILON, P., BOYD, D., ALI-OSMAN, F., STETLER-STEVENSON, W.G., LIOTTA, L.A. and SAWAYA, R., Role of plasminogen activator and 92-kDa type IV collagenase in glioblastoma invasion using an in vitro Matrigel model. J. Neurooncol., 18, 129-138 (1993).
264. REDLITZ, A., FOWLER, B.J., PLOW, E.F. and MILES, L.A., The role of an enolase-related molecule in plasminogen binding to cells. Europ. J. Biochem., 227, 407-415 (1995).
265. REDLITZ, A. and PLOW, E.F., Receptors for plasminogen and t-PA. An update. Bailliére's clin. Haematol., 8, 313-327 (1995).
266. REICH, R., THOMPSON, E.W., IWAMOTO, Y., MARTIN, G.R., DEASON, J.R., FULLER, G.C. and MISKIN, R., Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res., 48, 3307-3312 (1988).
267. REILLY, D., CHRISTENSEN, L., DUCH, M., NOLAN, N., DUFFY, M.J. and ANDREASEN, P.A., Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer, 50, 208-214 (1992).
268. 5-mediated adhesion of a human cell line (HaCaT) to vitronectin. Exp. Cell Res., 220, 274-282 (1995).
269. REITER, L.S., KRUITHOF, E.K.O., CAJOT, J.-F. and SORDAT, M., The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells. Int. J. Cancer, 53, 444-450 (1993).
270. RESNATI, M., GUTTINGER, M., VALCAMONICA, S., SIDENIUS, N., BLASI, F. and FAZIOLI, F., Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J., 15, 1572-1582 (1996).
271. RIFKIN, D.B., MOSCATELLI, D., BIZIK, J., QUARTO, N., BLEI, F., DENNIS, P., FLAUMENHAFT, R. and MIGNATTI, P., Growth factor control of extracellular proteolysis. Cell Differentiation Develop., 32, 313-318 (1990).
272. RIJKEN, D.C., Plasminogen activators and plasminogen activator inhibitors. Biochemical aspects. Bailliére's clin. Haematol., 8, 291-312 (1995).
273. ROLDAN, A.L., CUBELLIS, M.V., MASUCCI, M.T., BEHRENDT, N., LUND, L.R., DANØ, K., APPELLA, E. and BLASI, F., Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin-dependent proteolysis. EMBO J., 9, 467-474 (1990).
274. RØMER, J., PYKE, C., LUND, L.R., ERIKSEN, J., KRISTENSEN, P., RØNNE, E., HØYER-HANSEN, G.,DANØ, K. and BRÜNNER, N., Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int. J. Cancer, 57, 553-560 (1994).
275. 2-terminal domain of the urokinase-receptor. FEBS Lett., 288, 233-236 (1991).
276. SAITO, A., PIETROMONACO, S., LOO, A.K.-C. and FARQUHAR, M.G., Complete cloning and sequencing of rat gp330/"megalin", a distinctive member of the low density lipoprotein receptor gene family. Proc. nat. Acad. Sci. (Wash.), 91, 9725-9729 (1994).
277. SAKSELA, O. and RIFKIN, D.B., Cell-associated plasminogen activation. Regulation and physiological functions. Ann. Rev. Cell Biol., 4, 93-126 (1988).
278. SAKSELA, O. and RIFKIN, D.B., Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J. Cell Biol., 110, 767-775 (1990).
279. SALONEN, E.-M., SAKSELA, O., VARTIO, T., VAHERI, A., NIELSEN, L.S. and ZEUTHEN, J., Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J. biol. Chem., 260, 12302-12307 (1985).
280. SALONEN, E.-M., ZITTING, A. and VAHERI, A., Laminin interacts with plasminogen and its tissue-type activator. FEBS Lett., 172, 29-32 (1984).
281. SANTELL, L., MAROTTI, K., BARTFELD, N.S., BAYNHAM, P. and LEVIN, E.G., Disruption of microtubules inhibits the stimulation of tissue plasminogen activator expression and promotes plasminogen activator inhibitor type 1 expression in human endothelial cells. Exp. Cell Res., 201, 358-365 (1992).
282. SAPPINO, A.-P., BELIN, D., HUARTE, J., HIRSCHEL-SCHOLZ, S., SAURAT, J.-H. and VASSALLI, J.-D., Differential protease expression by cutaneous squamous and basal cell carcinomas. J. clin. Invest., 88, 1073-1079 (1991).
283. SATO, Y., TSUBO, R., LYONS, R., MOSES, H. and RIFKIN, D.B., Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J. Cell Biol., 111, 757-763 (1990).
284. SCHLECHTE, W., BRATTAIN, M. and BOYD, D., Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display. Cancer Comm., 2, 173-179 (1990).
285. SCHLECHTE, W., MURANO, G. and BOYD, D., Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res., 49, 6064-6069 (1989).
286. SCHMITT, M., JÄNICKE, F. and GRAEFF, H., Tumor-associated fibrinolysis: the prognostic relevance of plasminogen activators u-PA and t-PA in human breast cancer. Blood Coagul. Fibrinolysis, 1, 695-702 (1990).
287. 1 functions as a receptor for tenascin, fibronectin, and vitronectin. J. biol. Chem., 270, 23196-23202 (1995).
288. SEEBACHER, T., MANSKE, M., ZOLLER, J., CRABB, J. and BADE, E.G., The EGF-inducible protein EIP-1 of migrating and normal rat liver epithelial cells is identical to plasminogen activator inhibitor 1 and is a component of the ECM migration tracks. Exp. Cell Res., 203, 504-507 (1992).
289. SEIFFERT, D., KEETON, M., EGUCHI, Y., SAWDEY, M. and LOSKUTOFF, D.J., Detection of vitronectin mRNA in tissues and cells of the mouse. Proc. nat. Acad. Sci. (Wash.), 88, 9402-9406 (1991).
290. SHAPIRO, R.L., DUQUETTE, J.G., ROSES, D.F., NUNES, I., HARRIS, M.N., KAMINO, H., WILSON, E.L. and RIFKIN, D.B., Induction of primary cutaneous neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res., 56, 3597-3604 (1996).
291. SHIRASUNA, K., SAKA, M., HAYASHIDO, Y., YOSHIOKA, H., SUGIURA, T. and MATSUYA, T., Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation. Cancer Res., 53, 147-152 (1993).
292. SILVERSTEIN, R.L., HARPEL, P.C. and NACHMAN, R., Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin. J. biol. Chem., 261, 9959-9965 (1986).
293. SILVERSTEIN, R.L., LEUNG, L.L.K., HARPEL, P.C. and NACHMAN, R., Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator. J. clin. Invest., 74, 1625-1633 (1984).
294. SITRIN, R.G., TODD, R.F., PETTY, H.R., BROCK, T.G., SHOLLENBERGER, S.B., ALBRECHT, E. and GYETKO, M.R., The urokinase receptor (CD87) facilitates
295. SKRIVER, L., LARSSON, L.-I., KIELBERG, V., NIELSEN, L.S., ANDRESEN, P.B., KRISTENSEN, P. and DANØ, K., Immunohistochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell Biol., 99, 752-757 (1984).
296. SOFF, G.A., SANDEROWITZ, J., GATELY, S., VERRUSIO, E., WEISS, I., BREM, S. and KWAAN, H.C., Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J. clin. Invest., 96, 2593-2600 (1995).
297. SOLBERG, H., RØMER, J., BRÜNNER, N., HOLM, A., SIDENIUS, N., DANØ, K. and HØYER-HANSEN, G., A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int. J. Cancer, 58, 877-881 (1994).
298. SPIERS, E.M., LAZARUS, G.S. and LYONS-GIORDANO, B., Expression of plasminogen activators in basal cell carcinoma. J. Pathol., 178, 290-296 (1996).
299. SPRENGERS, E.D. and KLUFT, C., Plasminogen activator inhibitors. Blood, 69, 381-387 (1987).
300. SPYRATOS, F., MARTIN, P.-M., HACENE, K., ROMAIN, S., ANDRIEU, C., FERRERO-POUS, M., DEYTIEUX, LE DOUSSAL, V., TUBIANA-HULIN, M. and BRUNET, M., Multiparametric prognostic evaluation of biological factors in primary breast cancer. J. nat. Cancer Inst., 84, 1266-1272 (1992).
301. STACK, M.S. and JOHNSON, D.A., Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J. biol. Chem., 269, 9416-9419 (1994).
302. STAHL, A. and MUELLER, B.M., Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res., 54, 3066-3071 (1994).
303. 3 binding to vitronectin. Nature (Lond.), 383, 441-443 (1996).
304. STEFFENS, G.J., GÜNZLER, W.A., ÖTTING, F., FRANKUS, E. and FLOHÉ, L., The complete amino acid sequence of low molecular mass urokinase from human urine. Hoppe-Seyler's Z. physiol. Chem., 363, 1043-1058 (1982).
305. STEIN, P. and CARRELL, R.W., What do dysfunctional serpins tell us about molecular mobility and disease? Struct. Biol., 2, 96-113 (1995).
306. STEPHENS, R.W., PÖLLÄNEN, J., TAPIOVAARA, H., LEUNG, K.-C., SIM, P.-S.. SALONEN, E.-M., RØNNE, E., BEHRENDT, N., DANØ, K. and VAHERI, A., Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J. Cell Biol., 108, 1987-1995 (1989).
307. STOPPELLI, M.P., CORTI, A., SOFFIENTINI, A., CASSANI, G., BLASI, F. and ASSOIAN, R.K., Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. nat. Acad. Sci. (Wash.), 82, 4939-4943 (1985).
308. STOPPELLI, M.P., TACCHETTI, C., CUBELLIS, M.V., CORTI, A., HEARING, V.J., CASSANI, G., APPELLA, E. and BLASÍ. F., Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell, 45, 675-684 (1986).
309. STRICKLAND, O.K., KOUNNAS, M.Z., WILLIAMS, S.E. and ARGRAVES, W.S., LDL receptor-related protein (LRP): a multiligand receptor. Fibrinolysis, 8 (Suppl. 1), 204-215 (1994).
310. TAKAHASHI, K., IKEO, K., GOJOBORI, T. and TANIPUJI, M., Local function of urokinase receptor at the adhesion contact sites of a metastatic tumor cell. Thrombosis Res., 10, 55-61 (1990).
311. TESTA, J.E. and QUIGLEY, J.P., The role of urokinase-type plasminogen activator in aggressive tumor cell behaviour. Cancer Metastasis Rev., 9, 353-367 (1990).
312. TREMBLAY, G., Stromal aspects of breast carcinoma. Exp. mol. Pathol., 31, 248-260 (1979).
313. TSUBOI, R. and RIFKIN, D.B., Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity. Int. J. Cancer, 46, 56-60 (1990).
314. VAN ROY, F. and MAREEL, M., Tumor invasion: effects of cell adhesion and motility. Trends Cell Biol., 2, 163-169 (1992).
315. VARANI, J., ORR, W. and WARD, P.A., Cell-associated proteases affect tumor cell migration in vivo. J. Cell Sci., 36, 241-252 (1979).
316. VASSALLI, J.-D., The urokinase receptor. Fibrinolysis, 8 (Suppl. 1), 172-181 (1994).
317. r 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol., 100, 86-92 (1985).
318. VASSALLI, J.-D., SAPPINO, A.-P. and BELIN, D., The plasminogen activator/ plasmin system. J. clin. Invest., 88, 1067-1072 (1991).
319. WAGNER, S.N., ATKINSON, M.J., THANNER, S., WAGNER, C., SCHMITT, M., WILHELM, O., ROTTER, M. and HÖFFLER, H., Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am. J. Pathol., 147, 183-192 (1995).
320. WALTZ, D. and CHAPMAN, H., Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. biol. Chem., 269, 14746-14750 (1994).
321. WALTZ, D.A., SAILOR, L.Z. and CHAPMAN, H.A., Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J. clin. Invest., 91, 1541-1552 (1993).
322. WANG, N., PLANUS, E., POUCHELET, M., FREDBERG, J.J. and BARLOVATZ-MEIMON, G., Urokinase receptor mediates mechanical force across the cell surface. Amer. J. Physiol., 268, C1062-C1066 (1995).
323. WEI, Y., LUKASHEV, M., SIMON, D.I., BODARY, S.C., ROSENBERG, S., DOYLE, M.V. and CHAPMAN, H.A., Regulation of integrin function by the urokinase receptor. Science, 273, 1551-1555 (1996).
324. WEI, Y., WALTZ, D.A., RAO, N., DRUMMOND, R.J., ROSENBERG, S. and CHAPMAN, H.A., Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. biol. Chem., 269, 32380-32388 (1994).
325. WERB, Z., TREMBLE, P. and DAMSKY, C.H., Regulation of extracellular matrix degradation by cell-extracellular matrix interactions. Cell Differentiation Develop., 32, 299-306 (1990).
326. WILHELM, O., SCHMITT, M., HÖHL, S., SENEKOWITSCH, R. and GRAEFF, H., Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin. exp. Metastasis, 13, 296-302 (1995).
327. WILHELM, O., WEIDLE, U., HÖHL, S., RETTENBERGER, P., SCHMITT, M. and GRAEFF, H., Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). FEBS Lett., 337, 131-134 (1994).
328. WILLIAMS, M.J., HUGHES, P.E., O'TOOLE, T.E. and GINSBERG, M.H., The inner world of cell adhesion. Integrin cytoplasmic domains. Trends Cell Biol., 4, 109-112 (1994).
329. WILLNOW, T.E., GOLDSTEIN, J.L., ORTH, K., BROWN, M.S. and HERZ, J., LDL receptor related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J. biol. Chem., 267, 26172-26180 (1992).
330. WILLNOW, T.E., ORTH, K. and HERZ, J., Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein. J. biol. Chem., 269, 15827-15832 (1994).
331. WOLF, B.B., VASUDAVAN, J., HENKIN, J. and GONIAS, S.L., Nerve growth factor-γ activates soluble and receptor-bound single chain urokinase-type plasminogen activator. J. biol. Chem., 268, 16327-16331 (1993).
332. XING, R.H. and RABBANI, S.A., Overexpression of urokinase receptor in breast cancer results in increased tumor invasion, growth and metastasis. Int. J. Cancer, 67, 423-429 (1996).
333. XUE, W., KINDZELSKI, A.L., TODD, R.F. and PETTY, H.R., Physical association of complement type 3 receptor and urokinase-type plasminogen activator receptor in neutrophil membranes. J. Immunol., 152, 4630-4640 (1994).
334. YAMAMOTO, M., SAWAYA, R., MOHANAM, S., BINDAL, A.K., BRUNER, J.M., OKA, K., RAO, V.H., TOMONAGA, M., NICOLSON, G.L. and RAO, J.S., Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res., 54, 3656-3561 (1994a).
335. YAMAMOTO, M., SAWAYA, R., MOHANAM, S., LOSKUTOFF, D.J., BRUNER, J.M., RAO, V.H., OKA, K., TOMONAGA, M., NICOLSON, G.L. and RAO, J.S., Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo. Cancer Res., 54, 3329-3332 (1994b).
336. YAMAMOTO, M., SAWAYA, R., MOHANAM, S., RAO, V.H., BRUNER, J.M., NICOLSON, G.L. and RAO, J.S., Expression and localization of urokinase-type plasminogen activator receptor in gliomas. Cancer Res., 54, 5016-5020 (1994c).
337. YOSHIDA, E., OHMURA, S., SUGIKI, M., MARUYAMA, M. and MIHARA, H., Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int. J. Cancer, 63, 863-865 (1995).
338. YU, H. and SCHULTZ, R.M., Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res., 50, 7623-7633 (1990).
339. ZHENG, M.H., FAN, Y., PANICKER, A., SMITH, A., ROBERTSON, T., WYSOCKI, S., ROBBINS, P., PAPADIMITROU, J.M. and WOOD, D.J., Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization. Amer. J. Pathol., 147, 1559-1566 (1995).
340. ZHENG, X., SAUNDERS, T.L., CAMPER, S.A., SAMUELSON, L.C. and GINSBURG, D., Vitronectin is not essential for normal mammalian development and fertility. Proc. nat. Acad. Sci. (Wash.), 92, 12426-12430 (1995).